MDA Highlights ALS Research Advances, Advocacy Push Amidst Growing Patient Needs

Event summary

  • The Muscular Dystrophy Association (MDA) is focusing on ALS research and advocacy during May, designated ALS Awareness Month.
  • Researchers at NIH, led by Dr. Bryan Traynor, have identified a potential blood test for early ALS detection and are exploring drug repurposing strategies.
  • MDA has awarded nearly $2 million in ALS grants in 2025 and invested over $180 million in research to date.
  • MDA is advocating for the reauthorization of the ACT for ALS and passage of the ALS Better Care Act to expand access to care and improve quality of life.
  • Richard Govoni left a legacy gift of over $300,000 to MDA to advance ALS research, inspiring others to contribute.

The big picture

The MDA’s focus on ALS research and advocacy reflects a broader trend in neurodegenerative disease treatment – a shift from symptom management to early detection and targeted therapies. The organization's significant investment ($180M+) and partnerships underscore the growing recognition of ALS as a complex and urgent public health challenge. The emphasis on legislative advocacy highlights the critical role of policy in enabling research and improving patient access to care.

What we're watching

Legislative Risk
The reauthorization of the ACT for ALS and passage of the ALS Better Care Act are crucial for patient access and funding; failure to secure these could significantly impact care and research progress.
Diagnostic Adoption
The investigational blood test’s accuracy and regulatory approval will determine its adoption rate and impact on early diagnosis, potentially shifting clinical trial enrollment patterns.
Fundraising Sustainability
MDA’s reliance on fundraising campaigns, like the Fill the Boot and Dutch Bros initiatives, highlights the need to maintain donor engagement to sustain research and care programs.

Related topics

Philanthropy